We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts.
- Authors
Mahajan, Kunal; Chand Negi, Prakash; Ganju, Neeraj; Sondhi, Sachin; Gaur, Naresh; Somendra, Rao
- Abstract
The functional receptor to SARS-CoV-2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is angiotensin-converting enzyme-2 (ACE-2), the same enzyme that physiologically counters the renin-angiotensin system (RAS) activation. Some researchers have questioned RAS inhibitors' safety in COVID-19 patients since these drugs have demonstrated an increase in ACE-2 expression in preclinical studies; therefore, they may facilitate viral invasion. On the contrary, others have hypothesized a protective role of RAS inhibitors against COVID-19-associated lung injury. Overall, the data are grossly inadequate to reach any conclusion since no human trials have yet evaluated the effects of RAS inhibitors in COVID-19. We review the current data and pathophysiological mechanisms behind this intriguing interplay between the RAS inhibitors and the COVID-19.
- Subjects
ANGIOTENSINS; ACE inhibitors; PATIENT safety; RENIN; RENIN-angiotensin system; COVID-19; CHEMICAL inhibitors
- Publication
International Journal of Hypertension, 2020, p1
- ISSN
2090-0384
- Publication type
Article
- DOI
10.1155/2020/1025913